Improvements made by Accelerate Diagnostics to its antimicrobial susceptibility testing (AST) system, Accelerate Pheno^®, have been cleared by the US FDA. 

The new product features improved performance in AST for four important antibiotics used to treat Pseudomonas aeruginosa, as well as the addition of the combination of P. aeruginosa and aztreonam, an empiric antibiotic.

"These improvements to our PhenoTest BC kit will provide clinicians with an even wider array of results to inform highly tailored treatment options for patients with bacteremia and sepsis. We believe that these new tests will support improved patient outcomes and further strengthen the trust that laboratories place in our system," commented Shelley Campeau, Accelerate's Chief Scientific Officer.

Accelerate Diagnostics are also seeking FDA clearance for its Accelerate PhenoAST BC GN kit for Gram-negative bacteremia testing.